Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS by Hopkins, Seth C., Ogirala, Ajay, Worden, MaryAlice, Koblan, Kenneth S.

Get full text

A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels by Piacentino, Daria, Ogirala, Ajay, Lew, Robert, Loftus, Gregory, Worden, MaryAlice, Koblan, Kenneth S., Hopkins, Seth C.

Get full text

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects by Tsukada, Hironobu, Chen, Yu-Luan, Xiao, Guangqing, Lennek, Lisa, Milanovic, Snezana M., Worden, MaryAlice, Polhamus, Daniel G., Chiu, Yu-Yuan, Hopkins, Seth C., Galluppi, Gerald R.

Get full text

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia by Tsukada, Hironobu, Milanovic, Snezana M., Darpo, Borje, Xue, Hongqi, Xiong, Kuangnan, Tripp, Emily, Lennek, Lisa, Worden, MaryAlice, Hopkins, Seth C., Galluppi, Gerald R.

Get full text

A dose-optimization trial of laronidase (Aldurazyme ®) in patients with mucopolysaccharidosis I by Giugliani, Roberto, Rojas, Verónica Muñoz, Martins, Ana Maria, Valadares, Eugênia R., Clarke, Joe T.R., Góes, José E.C., Kakkis, Emil D., Worden, Mary Alice, Sidman, Marisa, Cox, Gerald F.

Get full text